662 related articles for article (PubMed ID: 24496381)
21. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
22. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
23. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
24. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
26. Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation.
Colardo M; Gargano D; Russo M; Petraroia M; Pensabene D; D'Alessandro G; Santoro A; Limatola C; Segatto M; Di Bartolomeo S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108181
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
29. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
[TBL] [Abstract][Full Text] [Related]
30. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
31. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
33. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
34. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
35. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
36. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
37. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
Guo NH; Zheng JF; Zi FM; Cheng J
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30455393
[No Abstract] [Full Text] [Related]
38. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
39. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
40. RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma.
Jermakowicz AM; Kurimchak AM; Johnson KJ; Bourgain-Guglielmetti F; Kaeppeli S; Affer M; Pradhyumnan H; Suter RK; Walters W; Cepero M; Duncan JS; Ayad NG
Sci Rep; 2024 Apr; 14(1):9284. PubMed ID: 38654040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
